The study, dubbed TACTI-004, will focus on first line NSCLC patients with a tumour proportion score (TPS) PD-L1 of greater than one per cent, as Efti has already received fast track designation for low TPS scores.” The
The study, dubbed TACTI-004, will focus on first line NSCLC...
-
- There are more pages in this discussion • 318 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 35.5¢ | 33.5¢ | $768.6K | 2.220M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 1105390 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 187570 | 18 |
View Market Depth
| Last trade - 11.51am 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |